Compare RVSB & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | PYXS |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.5M | 141.3M |
| IPO Year | 1997 | 2021 |
| Metric | RVSB | PYXS |
|---|---|---|
| Price | $6.67 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $8.22 |
| AVG Volume (30 Days) | 55.5K | ★ 742.5K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | $42.74 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $82.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.88 | $1.03 |
| 52 Week High | $6.67 | $5.55 |
| Indicator | RVSB | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 80.18 | 29.90 |
| Support Level | $5.23 | $1.29 |
| Resistance Level | N/A | $1.77 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 98.72 | 0.87 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment. Its operations into two operating segments, consisting of banking operations and trust and investment services, these operating segments are aggregated into a single reportable operating segment.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.